A team from the Keck School of Medicine at the University of Southern California conducted a pioneering study comparing five leading treatments for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. This research, published in the journal Lung Cancer, is the first to analyze the effectiveness of lorlatinib and brigatinib outside clinical trials. ALK+ lung cancer, which affects about 4% of lung cancer patients, often occurs in non-smokers and is driven by a faulty protein due to ALK gene mutations. The study analyzed data from 940 patients treated between 2016 and 2024, revealing that alectinib provided the longest median survival at 46.5 months and the longest treatment duration at 33.5 months. While lorlatinib showed promise, its benefits were not statistically significant. The research emphasizes the importance of real-world studies, as clinical trials often exclude patients with comorbidities, making the findings more applicable to broader patient populations. The results could influence future treatment guidelines, helping healthcare providers make more informed decisions based on a patient's overall health and cancer stage.